Skip to main content

Table 1 Demographic and Clinical Characteristics at Baseline

From: Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients

Patient characteristics

Study group, n = 30

Control group, n = 30

P

Gender (male), n (%)

21 (70)

19 (63.3)

0.58

Age (years) (mean)

58.17 ± 11.52

66.23 ± 13.31

0.15

Comorbid conditions, n (%)

 Diabetes mellitus

9 (30)

10 (33.3)

0.78

 Hypertension

15 (50)

12 (40)

0.43

 Coronary artery disease

5 (16.7)

8 (26.7)

0.34

 Cardiac failure

1 (3.3)

0.31

 Chronic Obstructive Pulmonary Disease

6 (20)

3 (10)

0.27

 Malignancy

1 (3.3)

0.36

 Immunodeficiency

1 (3.3)

0.31

Symptoms, n (%)

 Fever

15 (59)

13 (43.3)

0.60

 Cough

16 (53.3)

14 (46.7)

0.60

 Sore throat

3 (10)

1 (3.3)

0.30

 Dyspnea

23 (76.7)

19 (63.3)

0.26

 Headache

5 (16.7)

2 (6.7)

0.22

 Weakness

13 (43.3)

11 (3.7)

0.59

 Myalgia

9 (30)

7 (23.3)

0.55

 Diarrhea

1 (3.3)

0.31

 Nausea or vomiting

1 (3.3)

0.31

Signs (mean)

 Body temperature (0C)

36.9 ± 0.7

36.8 ± 0.8

0.15

 Heart rate (per minute)

88 ± 12

92 ± 18

0.47

 Respiratory rate (per minute)

24 ± 5

24.7 ± 0.7

0.92

 Systolic pressure (mmHg)

124.39 ± 15.60

124.61 ± 15.37

0.85

 Diastolic pressure (mmHg)

75.64 ± 9.79

73.43 ± 8.47

0.07

 Inspiratory ral, n (%)

11 (36.7)

19 (63.3)

0.03

 SOFA score (mean)

3.12 ± 1.9

2.83 ± 2.1

0.36

 Mechanic ventilation requirement, n (%)

1 (3.3)

1 (3.3)

0.98

Typical radiological findings, n (%)

29 (96.7)

27 (90)

0.30